DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundation

Intravenous thrombolysis and mechanical thrombectomy

Essential points for quick revision.

Synopsis

Select and prepare eligible patients for intravenous thrombolysis or mechanical thrombectomy while controlling avoidable delays, treatment-specific hazards and post-reperfusion complications.

  • Reperfusion decisions are made by an acute stroke service using disabling deficit, last-known-well, imaging, premorbid function, bleeding risk and patient wishes; age or NIHSS alone should not become an automatic exclusion.
  • NICE recommends tenecteplase or alteplase as intravenous thrombolysis options for selected acute ischaemic stroke within 4.5 hours when intracranial haemorrhage has been excluded and contraindications are addressed; use the locally commissioned stroke protocol.
  • Wake-up or later-presenting stroke may be thrombolysed when MRI or perfusion imaging demonstrates a favourable tissue pattern under current specialist protocols; clock time is not the only modern selection tool.

Key red flags

Suspected intracranial haemorrhage, active major bleeding or a known severe haemostatic abnormality requires immediate specialist review and usually precludes thrombolysis.

Investigation priorities

01
Non-contrast CT brainFirst step

Exclude intracranial haemorrhage and assess the extent of established infarction before either reperfusion treatment.

Management branches

LYSEIntravenous thrombolysis decision

A patient has a disabling acute ischaemic stroke within a standard or imaging-selected treatment window.

  1. Confirm last-known-well, deficit and premorbid function, exclude haemorrhage on imaging and review anticoagulants, bleeding, procedures, blood pressure and glucose with the stroke physician.
  2. Correct a treatable pressure excess carefully to the protocol threshold and obtain only laboratory results that are clinically necessary before treatment.

Key medicines

AlteplaseFor eligible acute ischaemic stroke, give 0.9 mg/kg intravenously to a maximum 90 mg, with 10% as an initial bolus and the remainder infused over 60 minutes.
TenecteplaseFor eligible adult acute ischaemic stroke, give 0.25 mg/kg intravenously to a maximum 25 mg as a single bolus, using the dedicated stroke presentation and exact local weight-band protocol.
Open full textbook Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom